# Nuclera

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nuclera

- Industry: Biotechnology
- Headquarters: Cambridge, UK
- Website: www.nuclera.com
- Total disclosed funding: $133M
- Latest round: Series C (Oct 15, 2024)
- Investors on record: 12

## About

Based in the UK, Nuclera Ltd operates as a biotech company that develops a digital platform to enable protein printing. Based in Cambridge, UK, and founded in 2013 by CEO Michel Chen, CFO Jiahao Huang, and CTO Gordon Mclnroy, Nuclera Ltd operates as a biotechnology company that accelerates the protein expression workflows through desktop enzymatic protein and gene synthesis. In January 2026, Nuclera Ltd raised USD 12 million in series C funding from Elevage Medical Technologies, LP, G. K. Goh Holdings and British Business Bank. The company product line includes eProtein synthesis, a desktop bioprinter that delivers proteins through the combination of cell-free technologies and digital microfluidics; eDrop digital microfluidics, a programmable lab-on-a-chip technology that employs eProtein and eDNA synthesis bio-inks to make drug discovery workflows accessible on the benchtop. Nuclera generates revenue by selling its eProtein Discovery benchtop bioprinter, smart cartridges, and related protein-synthesis consumables to biotech and pharmaceutical researchers seeking faster, automated protein access. The company will use the funding to add antibody expression and binding validation features to its eProtein Discovery system, enabling end-to-end antibody screening and supporting AI-driven biologics research.

## Funding rounds

- Series C, Oct 15, 2024, $75M — Cambridge Innovation Capital, Uni-Power Group, British Patient Capital, Verve Ventures, Elevage Medical Technologies, LP
- Series B, Mar 31, 2022, $15M — Verve Ventures
- Series B, Jan 27, 2022, $43M — Amadeus Capital Partners, G. K. Goh Holdings, British Business Bank, E Ink Corp., M&G, RT Partners, Future Planet Capital

## Investors

- Amadeus Capital Partners (https://capitalatlas.ai/funds/amadeus-capital-partners) — Series B
- G. K. Goh Holdings — Series B
- British Business Bank (https://capitalatlas.ai/funds/british-business-bank) — Series B
- E Ink Corp. — Series B
- M&G (https://capitalatlas.ai/funds/m-g) — Series B
- RT Partners — Series B
- Future Planet Capital (https://capitalatlas.ai/funds/future-planet-capital) — Series B
- Verve Ventures (https://capitalatlas.ai/funds/verve-ventures) — Series B, Series C
- Cambridge Innovation Capital (https://capitalatlas.ai/funds/cambridge-innovation-capital) — Series C
- Uni-Power Group — Series C
- British Patient Capital — Series C
- Elevage Medical Technologies, LP — Series C